Moleculin Biotech, Inc. (MBRX) Key Statistics & Financial Ratios

Moleculin Biotech, Inc. (MBRX) — Price $0.74 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for Moleculin Biotech, Inc. (MBRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.

Stock Data

Price$0.74
Market Cap$4M
Enterprise Value-$3.0M
ExchangeNASDAQ
CountryUS

Valuation Multiples

P/E Ratio-0.04
Price / Book0.36
P/S0.00
EV/EBITDA0.10
EV/Sales0.00
EV/FCF0.12
P/FCF-0.16
Earnings Yield-721.43%
FCF Yield-642.13%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-816.56%
Return on Assets-143.82%
Return on Invested Capital-242.25%
Return on Capital Employed-245.24%

Financial Health

Current Ratio0.94
Quick Ratio0.94
Cash Ratio0.78
Debt / Equity0.03
Debt / Assets1.38%
Net Debt / EBITDA0.23
Interest Coverage-370.18

Per-Share Data

Revenue per share0.00
Book Value per share2.04
Cash per share1.28
FCF per share-4.46
Tangible Book Value per share0.08
Dividend per share0.00

Related companies: ADAP · AIMD · APLM · ATHA · BLRX · CTXR · ICU

Explore sector: Healthcare · Biotechnology

More sections of MBRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks